Aligos Therapeutics (NASDAQ:ALGS) Price Target Cut to $70.00 by Analysts at HC Wainwright

Aligos Therapeutics (NASDAQ:ALGS) had its price target decreased by analysts at HC Wainwright from $75.00 to $70.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Aligos Therapeutics Trading Down 19.6 %

Shares of NASDAQ:ALGS opened at $10.41 on Tuesday. The company has a market cap of $37.35 million, a price-to-earnings ratio of -0.78 and a beta of 2.52. Aligos Therapeutics has a 12 month low of $6.76 and a 12 month high of $46.80. The company has a 50-day moving average price of $26.65 and a 200 day moving average price of $20.55.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings data on Monday, March 10th. The company reported ($13.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.63) by ($10.45). The company had revenue of $0.63 million during the quarter, compared to the consensus estimate of $0.43 million. Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. During the same period in the previous year, the business earned ($5.50) earnings per share. As a group, equities analysts forecast that Aligos Therapeutics will post -10.36 EPS for the current year.

Institutional Investors Weigh In On Aligos Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC boosted its stake in shares of Aligos Therapeutics by 2,073.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 652 shares of the company’s stock worth $26,000 after purchasing an additional 622 shares during the period. AlphaMark Advisors LLC lifted its stake in Aligos Therapeutics by 1,000.0% in the fourth quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock worth $44,000 after purchasing an additional 1,000 shares during the last quarter. Golden State Wealth Management LLC purchased a new position in shares of Aligos Therapeutics during the fourth quarter valued at approximately $107,000. Northern Trust Corp bought a new position in shares of Aligos Therapeutics during the fourth quarter valued at approximately $205,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Aligos Therapeutics by 19.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 14,286 shares of the company’s stock worth $569,000 after buying an additional 2,306 shares during the period. Hedge funds and other institutional investors own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).